Innovative approaches for the treatment of depression: Targeting the HPA axis

Neurochemical Research

Volumn 33, Issue 4, 2008, Pages 691-707

  Thomson, Fiona ^a   Craighead, Mark ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

AVP; Cortisol; CRF; Depression; HPA axis; Stress

Indexed keywords

11BETA (1,3 BENZODIOXOL 5 YL) 17BETA HYDROXY 17ALPHA (1 PROPYNYL)ESTRA 4,9 DIEN 3 ONE; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 4 (2 CHLORO 4 METHOXY 5 METHYLPHENYL) N [2 CYCLOPROPYL 1 (3 FLUORO 4 METHYLPHENYL)ETHYL] 5 METHYL N (2 PROPYNYL) 2 THIAZOLAMINE; 8 (2,4 DICHLOROPHENYL) 4 [2 METHOXY 1 (METHOXYMETHYL)ETHYLAMINO] 2,7 DIMETHYLPYRAZOLO[1,5 A][1,3,5]TRIAZINE; AMINOGLUTETHIMIDE; ANTALARMIN; ANTIDEPRESSANT AGENT; ARGIPRESSIN; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN RELEASING FACTOR; GLUCOCORTICOID RECEPTOR; KETOCONAZOLE; MIFEPRISTONE; MINERALOCORTICOID RECEPTOR; ORG 34116; ORG 34850; PENTAGASTRIN; SSR148415; TRANYLCYPROMINE; UNCLASSIFIED DRUG; VENLAFAXINE;

ANXIETY; DEPRESSION; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MENTAL STRESS; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; THALAMUS MIDLINE NUCLEUS;

EID: 40349094750     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-007-9518-3     Document Type: Review

References (183)

1. 1. RC Kessler WT Chiu O Demler KR Merikangas EE Walters 2005 Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication Arch Gen Psychiatry 62 617 627 15939839 10.1001/archpsyc.62.6.617 Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617–627
2. 2. M Fava 2003 Diagnosis and definition of treatment-resistant depression Biol Psychiatry 53 649 659 12706951 10.1016/S0006-3223(03)00231-2 Fava M (2003) Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53:649–659
3. 3. AF Schatzberg AJ Rothschild PJ Langlais PJ Langlais ED Bird JO Cole 1985 A corticosteroid/dopamine hypothesis for psychotic depression and related states J Psychiatr Res 19 57 64 2859366 1:CAS:528:DyaL2MXktVCmtL0%3D 10.1016/0022-3956(85)90068-8 Schatzberg AF, Rothschild AJ, Langlais PJ, Langlais PJ, Bird ED, Cole JO (1985) A corticosteroid/dopamine hypothesis for psychotic depression and related states. J Psychiatr Res 19:57–64
4. 4. P Putignano A Dubini P Toja C Invitti S Bonfanti G Redaelli D Zappulli F Cavagnini 2001 Salivary cortisol measurement in normal-weight, obese and anorexic women: comparison with plasma cortisol Eur J Endocrinol 145 165 171 11454512 1:CAS:528:DC%2BD3MXlvFCit7Y%3D 10.1530/eje.0.1450165 Putignano P, Dubini A, Toja P, Invitti C, Bonfanti S, Redaelli G, Zappulli D, Cavagnini F (2001) Salivary cortisol measurement in normal-weight, obese and anorexic women: comparison with plasma cortisol. Eur J Endocrinol 145:165–171
5. 5. RD Marshall C Blanco D Printz MR Liebowitz DF Klein J Coplan 2002 A pilot study of noradrenergic and HPA axis functioning in PTSD vs. panic disorder Psychiatry Res 110 219 230 12127472 1:CAS:528:DC%2BD38XlsVKrsbw%3D 10.1016/S0165-1781(02)00126-9 Marshall RD, Blanco C, Printz D, Liebowitz MR, Klein DF, Coplan J (2002) A pilot study of noradrenergic and HPA axis functioning in PTSD vs. panic disorder Psychiatry Res 110:219–230
6. 6. AW Zobel T Nickel A Sonntag M Uhr F Holsboer M Ising 2001 Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. A prospective study J Psychiatr Res 35 83 94 11377437 1:STN:280:DC%2BD3M3pslOrtw%3D%3D 10.1016/S0022-3956(01)00013-9 Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M (2001) Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. A prospective study. J Psychiatr Res 35:83–94
7. 7. AW Zobel A Yassouridis RM Frieboes F Holsboer 1999 Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression Am J Psychiatry 156 949 951 10360139 1:STN:280:DyaK1M3ovVCisw%3D%3D Zobel AW, Yassouridis A, Frieboes RM, Holsboer F (1999) Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. Am J Psychiatry 156:949–951
8. 8. FA Antoni MC Holmes GB Makara M Karteszi FA Laszlo 1984 Evidence that the effects of arginine-8-vasopressin (AVP) on pituitary corticotropin (ACTH) release are mediated by a novel type of receptor Peptides 5 519 522 6089144 1:CAS:528:DyaL2cXkvVChtrg%3D 10.1016/0196-9781(84)90080-9 Antoni FA, Holmes MC, Makara GB, Karteszi M, Laszlo FA (1984) Evidence that the effects of arginine-8-vasopressin (AVP) on pituitary corticotropin (ACTH) release are mediated by a novel type of receptor. Peptides 5:519–522
9. 9. W Vale J Spiess C Rivier J Rivier 1981 Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin Science 213 1394 1397 6267699 1:CAS:528:DyaL3MXlvF2htbc%3D 10.1126/science.6267699 Vale W, Spiess J, Rivier C, Rivier J (1981) Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213:1394–1397
10. 10. HJ Karl L Raith 1966 Corticosterone secretion in humans. 3. Secretory rate of corticosterone and cortisol during stimulation of the adrenal cortex with ACTH Klin Wochenschr 44 303 306 4294247 1:CAS:528:DyaF28Xos1Wnsw%3D%3D 10.1007/BF01752277 Karl HJ, Raith L (1966) Corticosterone secretion in humans. 3. Secretory rate of corticosterone and cortisol during stimulation of the adrenal cortex with ACTH. Klin Wochenschr 44:303–306
11. 11. A Munck PM Guyre NJ Holbrook 1984 Physiological functions of glucocorticoids in stress and their relation to pharmacological actions Endocr Rev 5 25 44 6368214 1:CAS:528:DyaL2cXhvVGrtrk%3D 10.1210/edrv-5-1-25 Munck A, Guyre PM, Holbrook NJ (1984) Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev 5:25–44
12. 12. RM Sapolsky LM Romero AU Munck 2000 How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions Endocr Rev 21 55 89 10696570 1:CAS:528:DC%2BD3cXhs12hu78%3D 10.1210/er.21.1.55 Sapolsky RM, Romero LM, Munck AU (2000) How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 21:55–89
13. 13. K Erickson W Drevets J Schulkin 2003 Glucocorticoid regulation of diverse cognitive functions in normal and pathological emotional states Neurosci Biobehav Rev 27 233 246 12788335 1:CAS:528:DC%2BD3sXkt1Giu7c%3D 10.1016/S0149-7634(03)00033-2 Erickson K, Drevets W, Schulkin J (2003) Glucocorticoid regulation of diverse cognitive functions in normal and pathological emotional states. Neurosci Biobehav Rev 27:233–246
14. 14. JM Reul ER Kloet de 1985 Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation Endocrinology 117 2505 2511 2998738 1:CAS:528:DyaL28XhsFegtA%3D%3D 10.1210/endo-117-6-2505 Reul JM, de Kloet ER (1985) Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology 117:2505–2511
15. 15. RL Spencer EA Young PH Choo BS McEwen 1990 Adrenal steroid type I. and type II receptor binding: estimates of in vivo receptor number, occupancy, and activation with varying level of steroid Brain Res 514 37 48 2357528 1:CAS:528:DyaK3cXktFOqu7c%3D 10.1016/0006-8993(90)90433-C Spencer RL, Young EA, Choo PH, McEwen BS (1990) Adrenal steroid type I. and type II receptor binding: estimates of in vivo receptor number, occupancy, and activation with varying level of steroid. Brain Res 514:37–48
16. 16. ER Kloet de NY Rots DT Berg Van den MS Oitzl 1994 Brain mineralocorticoid receptor function Ann NY Acad Sci 746 8 20 7825924 10.1111/j.1749-6632.1994.tb39204.x de Kloet ER, Rots NY, Van den Berg DT, Oitzl MS (1994) Brain mineralocorticoid receptor function. Ann NY Acad Sci 746:8–20
17. 17. F Holsboer N Barden 1996 Antidepressants and hypothalamic-pituitary-adrenocortical regulation Endocr Rev 17 187 205 8706631 1:CAS:528:DyaK28XislGitr8%3D Holsboer F, Barden N (1996) Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev 17:187–205
18. 18. PW Gold FK Goodwin GP Chrousos 1988 Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (1) N Engl J Med 319 348 353 3292920 1:CAS:528:DyaL1cXlsVOit78%3D 10.1056/NEJM198808113190606 Gold PW, Goodwin FK, Chrousos GP (1988) Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (1). N Engl J Med 319:348–353
19. 19. PW Gold FK Goodwin GP Chrousos 1988 Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (2) N Engl J Med 319 413 420 3041279 1:CAS:528:DyaL1cXlsVOgurk%3D 10.1056/NEJM198808183190706 Gold PW, Goodwin FK, Chrousos GP (1988) Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (2). N Engl J Med 319:413–420
20. 20. RM Post 1992 Transduction of psychosocial stress into the neurobiology of recurrent affective disorder Am J Psychiatry 149 999 1010 1353322 1:STN:280:DyaK38zktl2gtg%3D%3D Post RM (1992) Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 149:999–1010
21. 21. BJ Carroll GC Curtis BM Davies J Mendels AA Sugerman 1976 Urinary free cortisol excretion in depression Psychol Med 6 43 50 935296 1:CAS:528:DyaE28XktVemtbY%3D 10.1017/S0033291700007480 Carroll BJ, Curtis GC, Davies BM, Mendels J, Sugerman AA (1976) Urinary free cortisol excretion in depression. Psychol Med 6:43–50
22. 22. PW Gold DL Loriaux A Roy MA Kling JR Calabrese CH Kellner LK Nieman RM Post D Pickar W Gallucci 1986 Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing’s disease. Pathophysiologic and diagnostic implications N Engl J Med 314 1329 1335 3010108 1:STN:280:DyaL283gtlCktA%3D%3D 10.1056/NEJM198605223142101 Gold PW, Loriaux DL, Roy A, Kling MA, Calabrese JR, Kellner CH, Nieman LK, Post RM, Pickar D, Gallucci W (1986) Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing’s disease. Pathophysiologic and diagnostic implications. N Engl J Med 314:1329–1335
23. 23. U Halbreich GM Asnis R Shindledecker B Zumoff RS Nathan 1985 Cortisol secretion in endogenous depression. I. Basal plasma levels Arch Gen Psychiatry 42 904 908 4037990 1:STN:280:DyaL2Mzgs1WktA%3D%3D Halbreich U, Asnis GM, Shindledecker R, Zumoff B, Nathan RS (1985) Cortisol secretion in endogenous depression. I. Basal plasma levels. Arch Gen Psychiatry 42:904–908
24. 24. U Halbreich GM Asnis R Shindledecker B Zumoff RS Nathan 1985 Cortisol secretion in endogenous depression. II. Time-related functions Arch Gen Psychiatry 42 909 914 4037991 1:STN:280:DyaL2Mzgs1WktQ%3D%3D Halbreich U, Asnis GM, Shindledecker R, Zumoff B, Nathan RS (1985) Cortisol secretion in endogenous depression. II. Time-related functions. Arch Gen Psychiatry 42:909–914
25. 25. F Holsboer U Bardeleben Von A Gerken GK Stalla OA Muller 1984 Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression N Engl J Med 311 1127 6090905 1:STN:280:DyaL2M%2Fht1Gnsg%3D%3D Holsboer F, Von Bardeleben U, Gerken A, Stalla GK, Muller OA (1984) Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. N Engl J Med 311:1127
26. 26. CB Nemeroff E Widerlov G. H Bissette Walleus I Karlsson K Eklund CD Kilts PT Loosen W Vale 1984 Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients Science 226 1342 1344 6334362 1:STN:280:DyaL2M%2FmsFOrtg%3D%3D 10.1126/science.6334362 Nemeroff CB, Widerlov E, Bissette G. Walleus H, Karlsson I, Eklund K, Kilts CD, Loosen PT, Vale W (1984) Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 226:1342–1344
27. 27. EA Young J Kotun RF Haskett L Grunhaus JF Greden SJ Watson H Akil 1993 Dissociation between pituitary and adrenal suppression to dexamethasone in depression Arch Gen Psychiatry 50 395 403 8489328 1:STN:280:DyaK3s3ls1KrsQ%3D%3D Young EA, Kotun J, Haskett RF, Grunhaus L, Greden JF, Watson SJ, Akil H (1993) Dissociation between pituitary and adrenal suppression to dexamethasone in depression. Arch Gen Psychiatry 50:395–403
28. 28. RG Kathol R Anton R Noyes T Gehris 1989 Direct comparison of urinary free cortisol excretion in patients with depression and panic disorder Biol Psychiatry 25 873 878 2720002 1:STN:280:DyaL1M3kslGrtQ%3D%3D 10.1016/0006-3223(89)90267-9 Kathol RG, Anton R, Noyes R, Gehris T (1989) Direct comparison of urinary free cortisol excretion in patients with depression and panic disorder. Biol Psychiatry 25:873–878
29. 29. M Deuschle U Schweiger C Weber U Gotthardt A Korner J Schmider H Standhardt CH Lammers I Heuser 1997 Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls J Clin Endocrinol Metab 82 234 238 8989265 1:CAS:528:DyaK2sXkt1Kgsw%3D%3D 10.1210/jc.82.1.234 Deuschle M, Schweiger U, Weber C, Gotthardt U, Korner A, Schmider J, Standhardt H, Lammers CH, Heuser I (1997) Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J Clin Endocrinol Metab 82:234–238
30. 30. JD Amsterdam G Maislin A Winokur M Kling P Gold 1987 Pituitary and adrenocortical responses to the ovine corticotropin releasing hormone in depressed patients and healthy volunteers Arch Gen Psychiatry 44 775 781 2820340 1:CAS:528:DyaL1cXot1c%3D Amsterdam JD, Maislin G, Winokur A, Kling M, Gold P (1987) Pituitary and adrenocortical responses to the ovine corticotropin releasing hormone in depressed patients and healthy volunteers. Arch Gen Psychiatry 44:775–781
31. 31. TG Dinan S O’Brien E Lavelle LV Scott 2004 Further neuroendocrine evidence of enhanced vasopressin V3 receptor responses in melancholic depression Psychol Med 34 169 172 14971638 1:STN:280:DC%2BD2c%2Fot1Srug%3D%3D 10.1017/S0033291703001004 Dinan TG, O’Brien S, Lavelle E, Scott LV (2004) Further neuroendocrine evidence of enhanced vasopressin V3 receptor responses in melancholic depression. Psychol Med 34:169–172
32. 32. JC Nelson JM Davis 1997 DST studies in psychotic depression: a meta-analysis Am J Psychiatry 154 1497 1503 9356556 1:STN:280:DyaK1c%2FhvFeluw%3D%3D Nelson JC, Davis JM (1997) DST studies in psychotic depression: a meta-analysis. Am J Psychiatry 154:1497–1503
33. 33. JL Abelson GC Curtis 1996 Hypothalamic-pituitary-adrenal axis activity in panic disorder. 24-hour secretion of corticotropin and cortisol Arch Gen Psychiatry 53 323 331 8634010 1:CAS:528:DyaK28Xis1Oluro%3D Abelson JL, Curtis GC (1996) Hypothalamic-pituitary-adrenal axis activity in panic disorder. 24-hour secretion of corticotropin and cortisol. Arch Gen Psychiatry 53:323–331
34. 34. JD Bremner J Licinio A Darnell JH Krystal MJ Owens SM Southwick CB Nemeroff DS Charney 1997 Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder Am J Psychiatry 154 624 629 9137116 1:STN:280:DyaK2s3ot12rsA%3D%3D Bremner JD, Licinio J, Darnell A, Krystal JH, Owens MJ, Southwick SM, Nemeroff CB, Charney DS (1997) Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry 154:624–629
35. 35. CS Kloet de E Vermettenm E Geuze A Kavelaars CJ Heijnen HG Westenberg 2006 Assessment of HPA-axis function in posttraumatic stress disorder: pharmacological and non-pharmacological challenge tests, a review J Psychiatr Res 40 550 567 16214171 10.1016/j.jpsychires.2005.08.002 de Kloet CS, Vermettenm E, Geuze E, Kavelaars A, Heijnen CJ, Westenberg HG (2006) Assessment of HPA-axis function in posttraumatic stress disorder: pharmacological and non-pharmacological challenge tests, a review. J Psychiatr Res 40:550–567
36. 36. BJ Carroll M Feinberg JF Greden J Tarika AA Albala RF Haskett NM James Z Kronfol N Lohr M Steiner JP Vigne de E Young 1981 A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility Arch Gen Psychiatry 38 15 22 7458567 1:STN:280:DyaL3M7gvVOlsA%3D%3D Carroll BJ, Feinberg M, Greden JF, Tarika J, Albala AA, Haskett RF, James NM, Kronfol Z, Lohr N, Steiner M, de Vigne JP, Young E (1981) A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch Gen Psychiatry 38:15–22
37. 37. F Holsboer U Bardeleben Von K Wiedemann OA Muller GK Stalla 1987 Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression. Implications for pathophysiology of DST nonsuppression Biol Psychiatry 22 228 234 3028512 1:STN:280:DyaL2s7ivFWguw%3D%3D 10.1016/0006-3223(87)90237-X Holsboer F, Von Bardeleben U, Wiedemann K, Muller OA, Stalla GK (1987) Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression. Implications for pathophysiology of DST nonsuppression. Biol Psychiatry 22:228–234
38. 38. U Bardeleben Von F Holsboer 1991 Effect of age on the cortisol response to human corticotropin-releasing hormone in depressed patients pretreated with dexamethasone Biol Psychiatry 29 1042 1050 10.1016/0006-3223(91)90360-X Von Bardeleben U, Holsboer F (1991) Effect of age on the cortisol response to human corticotropin-releasing hormone in depressed patients pretreated with dexamethasone. Biol Psychiatry 29:1042–1050
39. 39. I Heuser A Yassouridis F Holsboer 1994 The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders J Psychiatr Res 28 341 356 7877114 1:STN:280:DyaK2M7ot1equw%3D%3D 10.1016/0022-3956(94)90017-5 Heuser I, Yassouridis A, Holsboer F (1994) The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res 28:341–356
40. 40. S Modell A Yassouridis J Huber F Holsboer 1997 Corticosteroid receptor function is decreased in depressed patients Neuroendocrinology 65 216 222 9088003 1:CAS:528:DyaK2sXit1Sit7c%3D 10.1159/000127275 Modell S, Yassouridis A, Huber J, Holsboer F (1997) Corticosteroid receptor function is decreased in depressed patients. Neuroendocrinology 65:216–222
41. 41. S Ridder S Chourbaji R Hellweg A Urani C Zacher W Schmid M Zink H Hortnagl H Flor FA Henn G Schutz P Gass 2005 Mice with genetically altered glucocorticoid receptor expression show altered sensitivity for stress-induced depressive reactions J Neurosci 25 6243 6250 15987954 1:CAS:528:DC%2BD2MXmtFKntLc%3D 10.1523/JNEUROSCI.0736-05.2005 Ridder S, Chourbaji S, Hellweg R, Urani A, Zacher C, Schmid W, Zink M, Hortnagl H, Flor H, Henn FA, Schutz G, Gass P (2005) Mice with genetically altered glucocorticoid receptor expression show altered sensitivity for stress-induced depressive reactions. J Neurosci 25:6243–6250
42. 42. JM Reul I Stec M Soder F Holsboer 1993 Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system Endocrinology 133 312 320 8391426 1:CAS:528:DyaK3sXlsFajs7w%3D 10.1210/en.133.1.312 Reul JM, Stec I, Soder M, Holsboer F (1993) Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 133:312–320
43. 43. JM Reul MS Labeur DE Grigoriadis EB Souza De F Holsboer 1994 Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide Neuroendocrinology 60 509 519 7845541 1:CAS:528:DyaK2cXmvFalu7k%3D 10.1159/000126788 Reul JM, Labeur MS, Grigoriadis DE, De Souza EB, Holsboer F (1994) Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology 60:509–519
44. 44. I Kitayama AM Janson A Cintra K Fuxe LF Agnati SO Ogren A Harfstrand P Eneroth JA Gustafsson 1988 Effects of chronic imipramine treatment on glucocorticoid receptor immunoreactivity in various regions of the rat brain. Evidence for selective increases of glucocorticoid receptor immunoreactivity in the locus coeruleus and in 5-hydroxytryptamine nerve cell groups of the rostral ventromedial medulla J Neural Transm 73 191 203 3210008 1:CAS:528:DyaL1cXlvVens70%3D 10.1007/BF01250136 Kitayama I, Janson AM, Cintra A, Fuxe K, Agnati LF, Ogren SO, Harfstrand A, Eneroth P, Gustafsson JA (1988) Effects of chronic imipramine treatment on glucocorticoid receptor immunoreactivity in various regions of the rat brain. Evidence for selective increases of glucocorticoid receptor immunoreactivity in the locus coeruleus and in 5-hydroxytryptamine nerve cell groups of the rostral ventromedial medulla. J Neural Transm 73:191–203
45. 45. JR Seckl G Fink 1992 Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo Neuroendocrinology 55 621 626 1321353 1:CAS:528:DyaK38XitVOksLs%3D 10.1159/000126180 Seckl JR, Fink G (1992) Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology 55:621–626
46. 46. MC Pepin S Beaulieu N Barden 1989 Antidepressants regulate glucocorticoid receptor messenger RNA concentrations in primary neuronal cultures Brain Res Mol Brain Res 6 77 83 2770454 1:CAS:528:DyaL1MXkvFShur0%3D 10.1016/0169-328X(89)90031-4 Pepin MC, Beaulieu S, Barden N (1989) Antidepressants regulate glucocorticoid receptor messenger RNA concentrations in primary neuronal cultures. Brain Res Mol Brain Res 6:77–83
47. 47. FC Raadsheer WJ Hoogendijk FC FJ Stam Tilders DF Swaab 1994 Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients Neuroendocrinology 60 436 444 7824085 1:STN:280:DyaK2M7isVGisg%3D%3D 10.1159/000126778 Raadsheer FC, Hoogendijk WJ, Stam FC Tilders FJ, Swaab DF (1994) Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 60:436–444
48. 48. M Altemus T Pigott KT Kalogeras M Demitrack B Dubbert DL Murphy PW Gold 1992 Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder Arch Gen Psychiatry 49 9 20 1370198 1:CAS:528:DyaK38XmtFSjtbk%3D Altemus M, Pigott T, Kalogeras KT, Demitrack M, Dubbert B, Murphy DL, Gold PW (1992) Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder. Arch Gen Psychiatry 49:9–20
49. 49. TD Geracioti Jr PT Loosen DN Orth 1997 Low cerebrospinal fluid corticotropin-releasing hormone concentrations in eucortisolemic depression Biol Psychiatry 42 165 174 9232208 1:CAS:528:DyaK2sXlt1Crs7o%3D 10.1016/S0006-3223(96)00312-5 Geracioti TD Jr, Loosen PT, Orth DN (1997) Low cerebrospinal fluid corticotropin-releasing hormone concentrations in eucortisolemic depression. Biol Psychiatry 42:165–174
50. 50. MA Kling A Roy AR Doran JR Calabrese DR Rubinow HJ Whitfield Jr C May RM Post GP Chrousos PW Gold 1991 Cerebrospinal fluid immunoreactive corticotropin-releasing hormone and adrenocorticotropin secretion in Cushing’s. disease and major depression: potential clinical implications J Clin Endocrinol Metab 72 260 271 1846869 1:STN:280:DyaK3M7itleitw%3D%3D 10.1210/jcem-72-2-260 Kling MA, Roy A, Doran AR, Calabrese JR, Rubinow DR, Whitfield HJ Jr, May C, Post RM, Chrousos GP, Gold PW (1991) Cerebrospinal fluid immunoreactive corticotropin-releasing hormone and adrenocorticotropin secretion in Cushing’s. disease and major depression: potential clinical implications. J Clin Endocrinol Metab 72:260–271
51. 51. AF Pitts SD Samuelson WH Meller G Bissette CB Nemeroff RG Kathol 1995 Cerebrospinal fluid corticotropin-releasing hormone, vasopressin, and oxytocin concentrations in treated patients with major depression and controls Biol Psychiatry 38 330 335 7495928 1:CAS:528:DyaK2MXoslKiu78%3D 10.1016/0006-3223(95)00229-A Pitts AF, Samuelson SD, Meller WH, Bissette G, Nemeroff CB, Kathol RG (1995) Cerebrospinal fluid corticotropin-releasing hormone, vasopressin, and oxytocin concentrations in treated patients with major depression and controls. Biol Psychiatry 38:330–335
52. 52. F Holsboer 1999 The rationale for corticotropin-releasing hormone receptor (CRH-R.) antagonists to treat depression and anxiety J Psychiatr Res 33 181 214 10367986 1:STN:280:DyaK1M3psVCmsA%3D%3D 10.1016/S0022-3956(98)90056-5 Holsboer F (1999) The rationale for corticotropin-releasing hormone receptor (CRH-R.) antagonists to treat depression and anxiety. J Psychiatr Res 33:181–214
53. 53. CB Nemeroff MJ Owens G Bissette AC Andorn M Stanley 1988 Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims Arch Gen Psychiatry 45 577 579 2837159 1:STN:280:DyaL1c3jvF2nsw%3D%3D Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M (1988) Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 45:577–579
54. 54. R Rupprecht KP Lesch U Muller G Beck H Beckmann HM Schulte 1989 Blunted adrenocorticotropin but normal beta-endorphin release after human corticotropin-releasing hormone administration in depression J Clin Endocrinol Metab 69 600 603 2547828 1:STN:280:DyaL1MzktVOqtQ%3D%3D 10.1210/jcem-69-3-600 Rupprecht R, Lesch KP, Muller U, Beck G, Beckmann H, Schulte HM (1989) Blunted adrenocorticotropin but normal beta-endorphin release after human corticotropin-releasing hormone administration in depression. J Clin Endocrinol Metab 69:600–603
55. 55. M Altemus SE Swedo HL Leonard D Richter DR Rubinow WZ Potter JL Rapoport 1994 Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine Arch Gen Psychiatry 51 794 803 7524463 1:STN:280:DyaK2M%2FjtFGluw%3D%3D Altemus M, Swedo SE, Leonard HL, Richter D, Rubinow DR, Potter WZ, Rapoport JL (1994) Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. Arch Gen Psychiatry 51:794–803
56. 56. CM Banki L Karmacsi G Bissette CB Nemeroff 1992 CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse Eur Neuropsychopharmacol 2 107 113 1352999 1:CAS:528:DyaK38XmsVGgtL0%3D 10.1016/0924-977X(92)90019-5 Banki CM, Karmacsi L, Bissette G, Nemeroff CB (1992) CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse. Eur Neuropsychopharmacol 2:107–113
57. 57. MD Bellis De PW Gold TD Geracioti Jr SJ Listwak MA Kling 1993 Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression Am J Psychiatry 150 656 657 8465888 De Bellis MD, Gold PW, Geracioti TD Jr, Listwak SJ, Kling MA (1993) Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry 150:656–657
58. 58. CB Nemeroff G Bissette H Akil M Fink 1991 Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, beta-endorphin and somatostatin Br J Psychiatry 158 59 63 1673078 1:STN:280:DyaK3M7pvVKrtw%3D%3D 10.1192/bjp.158.1.59 Nemeroff CB, Bissette G, Akil H, Fink M (1991) Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, beta-endorphin and somatostatin. Br J Psychiatry 158:59–63
59. 59. LS Brady PW Gold M Herkenham AB Lynn HJ Whitfield Jr 1992 The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications Brain Res 572 117 125 1351783 1:CAS:528:DyaK38XhvVOrurc%3D 10.1016/0006-8993(92)90459-M Brady LS, Gold PW, Herkenham M, Lynn AB, Whitfield HJ Jr (1992) The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res 572:117–125
60. 60. LS Brady HJ Whitfield Jr RJ Fox PW Gold M Herkenham 1991 Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications J Clin Invest 87 831 837 1671867 1:CAS:528:DyaK3MXhsFOis7g%3D 10.1172/JCI115086 Brady LS, Whitfield HJ Jr, Fox RJ, Gold PW, Herkenham M (1991) Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J Clin Invest 87:831–837
61. 61. JB Jensen DS Jessop MS Harbuz MS Harbuz A Mork C Sanchez JD Mikkelsen 1999 Acute and long-term treatments with the selective serotonin reuptake inhibitor citalopram modulate the HPA axis activity at different levels in male rats J Neuroendocrinol 11 465 471 10336728 1:CAS:528:DyaK1MXjs1ygsr0%3D 10.1046/j.1365-2826.1999.00362.x Jensen JB, Jessop DS, Harbuz MS, Harbuz MS, Mork A, Sanchez C, Mikkelsen JD (1999) Acute and long-term treatments with the selective serotonin reuptake inhibitor citalopram modulate the HPA axis activity at different levels in male rats. J Neuroendocrinol 11:465–471
62. 62. SC Stout MJ Owens CB Nemeroff 2002 Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatment J Pharmacol Exp Ther 300 1085 1092 11861819 1:CAS:528:DC%2BD38XitVelsbY%3D 10.1124/jpet.300.3.1085 Stout SC, Owens MJ, Nemeroff CB (2002) Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatment. J Pharmacol Exp Ther 300:1085–1092
63. 63. DE Grigoriadis D Pearsall EB Souza De 1989 Effects of chronic antidepressant and benzodiazepine treatment on corticotropin-releasing-factor receptors in rat brain and pituitary Neuropsychopharmacology 2 53 60 2553044 1:CAS:528:DyaL1MXitVGmsb8%3D 10.1016/0893-133X(89)90007-9 Grigoriadis DE, Pearsall D, De Souza EB (1989) Effects of chronic antidepressant and benzodiazepine treatment on corticotropin-releasing-factor receptors in rat brain and pituitary. Neuropsychopharmacology 2:53–60
64. 64. HM Praag van 2004 Let the facts prevail World J Biol Psychiatry 5 116 15179672 10.1080/15622970410029921 van Praag HM (2004) Let the facts prevail. World J Biol Psychiatry 5:116
65. 65. EP Zorrilla GR Valdez J Nozulak GF Koob A Markou 2002 Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat Brain Res 952 188 199 12376179 1:CAS:528:DC%2BD38Xns1ahsbw%3D 10.1016/S0006-8993(02)03189-X Zorrilla EP, Valdez GR, Nozulak J, Koob GF, Markou A (2002) Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res 952:188–199
66. 66. C Song C Earley BE Leonard 1995 Behavioral, neurochemical, and immunological responses to CRF administration. Is CRF a mediator of stress? Ann NY Acad Sci 771 55 72 8597429 1:CAS:528:DyaK28XitlKnu74%3D 10.1111/j.1749-6632.1995.tb44670.x Song C, Earley C, Leonard BE (1995) Behavioral, neurochemical, and immunological responses to CRF administration. Is CRF a mediator of stress? Ann NY Acad Sci 771:55–72
67. 67. DN Jones R Kortekaas PD Slade DN Middlemiss JJ Hagan 1998 The behavioural effects of corticotropin-releasing factor-related peptides in rats Psychopharmacology 138 124 132 9718281 1:CAS:528:DyaK1cXltlertr0%3D 10.1007/s002130050654 Jones DN, Kortekaas R, Slade PD, Middlemiss DN, Hagan JJ (1998) The behavioural effects of corticotropin-releasing factor-related peptides in rats. Psychopharmacology 138:124–132
68. 68. MP Stenzel-Poore SC Heinrichs S Rivest GF Koob WW Vale 1994 Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior J Neurosci 14 2579 2584 8182429 1:STN:280:DyaK2c3jvVehug%3D%3D Stenzel-Poore MP, Heinrichs SC, Rivest S, Koob GF, Vale WW (1994) Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J Neurosci 14:2579–2584
69. 69. SC Heinrichs H Min S Tamraz M Carmouche SA Boehme WW Vale 1997 Anti-sexual and anxiogenic behavioral consequences of corticotropin-releasing factor overexpression are centrally mediated Psychoneuroendocrinology 22 215 224 9226726 1:CAS:528:DyaK2sXkslamsrY%3D 10.1016/S0306-4530(97)00030-9 Heinrichs SC, Min H, Tamraz S, Carmouche M, Boehme SA, Vale WW (1997) Anti-sexual and anxiogenic behavioral consequences of corticotropin-releasing factor overexpression are centrally mediated. Psychoneuroendocrinology 22:215–224
70. 70. MM Gaalen van MP Stenzel-Poore F Holsboer T Steckler 2002 Effects of transgenic overproduction of CRH on anxiety-like behaviour Eur J Neurosci 15 2007 2015 12099906 10.1046/j.1460-9568.2002.02040.x van Gaalen MM, Stenzel-Poore MP, Holsboer F, Steckler T (2002) Effects of transgenic overproduction of CRH on anxiety-like behaviour. Eur J Neurosci 15:2007–2015
71. 71. G Liebsch R Landgraf R Gerstberger JC Probst CT Wotjak M Engelmann F Holsboer A Montkowski 1995 Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats Regul Pept 59 229 239 8584759 1:CAS:528:DyaK2MXos1ajtrk%3D 10.1016/0167-0115(95)00099-W Liebsch G, Landgraf R, Gerstberger R, Probst JC, Wotjak CT, Engelmann M, Holsboer F, Montkowski A (1995) Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul Pept 59:229–239
72. 72. GW Smith JM Aubry F Dellu A Contarino LM Bilezikjian LH Gold R Chen Y Marchuk C Hauser CA Bentley PE Sawchenko GF Koob W Vale KF Lee 1998 Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development Neuron 20 1093 1102 9655498 1:CAS:528:DyaK1cXktFOlurg%3D 10.1016/S0896-6273(00)80491-2 Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikjian LM, Gold LH, Chen R, Marchuk Y, Hauser C, Bentley CA, Sawchenko PE, Koob GF, Vale W, Lee KF (1998) Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20:1093–1102
73. 73. P Timpl R Spanagel I. A Sillaber Kresse JM Reul GK Stalla V Blanquet T Steckler F Holsboer W Wurst 1998 Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor Nat Genet 19 162 166 9620773 1:CAS:528:DyaK1cXls1Crtb8%3D 10.1038/520 Timpl P, Spanagel R, Sillaber I. Kresse A, Reul JM, Stalla GK, Blanquet V, Steckler T, Holsboer F, Wurst W (1998) Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor. Nat Genet 19:162–166
74. 74. MB Muller S Zimmermann I Sillaber TP Hagemeyer JM Deussing P Timpl MS Kormann SK Droste R Kuhn JM Reul F Holsboer W Wurst 2003 Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress Nat Neurosci 6 1100 1107 12973355 10.1038/nn1123 1:CAS:528:DC%2BD3sXnsFamtbg%3D Muller MB, Zimmermann S, Sillaber I, Hagemeyer TP, Deussing JM, Timpl P, Kormann MS, Droste SK, Kuhn R, Reul JM, Holsboer F, Wurst W (2003) Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat Neurosci 6:1100–1107
75. 75. JS Purba WJ Hoogendijk MA Hofman DF Swaab 1996 Increased number of vasopressin-and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression Arch Gen Psychiatry 53 137 143 8629889 1:STN:280:DyaK283itlGqug%3D%3D Purba JS, Hoogendijk WJ, Hofman MA, Swaab DF (1996) Increased number of vasopressin-and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry 53:137–143
76. 76. JN Zhou RF Riemersma UA WJ Unmehopam Hoogendijk JJ Heerikhuize van MA Hofman DF Swaab 2001 Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression Arch Gen Psychiatry 58 655 662 11448372 1:STN:280:DC%2BD3Mvisl2ltA%3D%3D 10.1001/archpsyc.58.7.655 Zhou JN, Riemersma RF, Unmehopam UA Hoogendijk WJ, van Heerikhuize JJ, Hofman MA, Swaab DF (2001) Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression. Arch Gen Psychiatry 58:655–662
77. 77. RF Winter de AM Hemert van RH DeRijk KH Zwinderman AC Frankhuijzen-Sierevogel VM Wiegant JG Goekoop 2003 Anxious-retarded depression: relation with plasma vasopressin and cortisol Neuropsychopharmacology 28 140 147 12496950 10.1038/sj.npp.1300002 1:CAS:528:DC%2BD3sXhtlWitrs%3D de Winter RF, van Hemert AM, DeRijk RH, Zwinderman KH, Frankhuijzen-Sierevogel AC, Wiegant VM, Goekoop JG (2003) Anxious-retarded depression: relation with plasma vasopressin and cortisol. Neuropsychopharmacology 28:140–147
78. 78. L Londen van JG Goekoop GM Kempen van AC Frankhuijzen-Sierevogel VM Wiegant EA Velde van der D Wied De 1997 Plasma levels of arginine vasopressin elevated in patients with major depression Neuropsychopharmacology 17 284 292 9326754 10.1016/S0893-133X(97)00054-7 van Londen L, Goekoop JG, van Kempen GM, Frankhuijzen-Sierevogel AC, Wiegant VM, van der Velde EA, De Wied D (1997) Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 17:284–292
79. 79. J Brunner ME Keck R Landgraf M Uhr C Namendorf T Bronisch 2002 Vasopressin in CSF and plasma in depressed suicide attempters: preliminary results Eur Neuropsychopharmacology 12 489 494 1:CAS:528:DC%2BD38Xms1yhsb4%3D 10.1016/S0924-977X(02)00071-8 Brunner J, Keck ME, Landgraf R, Uhr M, Namendorf C, Bronisch T (2002) Vasopressin in CSF and plasma in depressed suicide attempters: preliminary results. Eur Neuropsychopharmacology 12:489–494
80. 80. PS Sorensen A Gjerris M Hammer 1985 Cerebrospinal fluid vasopressin in neurological and psychiatric disorders J Neurol Neurosurg Psychiatry 48 50 57 3973621 1:STN:280:DyaL2M7jtlOhuw%3D%3D 10.1136/jnnp.48.1.50 Sorensen PS, Gjerris A, Hammer M (1985) Cerebrospinal fluid vasopressin in neurological and psychiatric disorders. J Neurol Neurosurg Psychiatry 48:50–57
81. 81. A Gjerris M Hammer P Vendsborg NJ Christensen OJ Rafaelsen 1985 Cerebrospinal fluid vasopressin-changes in depression Br J Psychiatry 147 696 701 3938307 1:STN:280:DyaL287mtVKhsA%3D%3D 10.1192/bjp.147.6.696 Gjerris A, Hammer M, Vendsborg P, Christensen NJ, Rafaelsen OJ (1985) Cerebrospinal fluid vasopressin-changes in depression. Br J Psychiatry 147:696–701
82. 82. JL Abelson J Melledo Le DG Bichet 2001 Dose response of arginine vasopressin to the CCK-C agonist pentagastrin Neuropsychopharmacology 24 161 169 11120398 1:CAS:528:DC%2BD3cXovFelsrc%3D 10.1016/S0893-133X(00)00182-2 Abelson JL, Le Melledo J, Bichet DG (2001) Dose response of arginine vasopressin to the CCK-C agonist pentagastrin. Neuropsychopharmacology 24:161–169
83. 83. BJ Carroll 1972 Stimulation tests in depression B Davies BJ Carroll RM Mowbray Depressive illness: some research studies CC Thomas Springfield 151 153 Carroll BJ (1972) Stimulation tests in depression. In: Davies B, Carroll BJ, Mowbray RM (eds) Depressive illness: some research studies. CC Thomas, Springfield, pp 151–153
84. 84. DD Krahn WH Meller RB Shafer JE Morley 1985 Cortisol response to vasopressin in depression Biol Psychiatry 20 918 921 2992617 1:STN:280:DyaL2M3otVKltg%3D%3D 10.1016/0006-3223(85)90217-3 Krahn DD, Meller WH, Shafer RB, Morley JE (1985) Cortisol response to vasopressin in depression. Biol Psychiatry 20:918–921
85. 85. TG Dinan E Lavelle LV Scott J Newell-Price S Medbak AB Grossman 1999 Desmopressin normalizes the blunted adrenocorticotropin response to corticotropin-releasing hormone in melancholic depression: evidence of enhanced vasopressinergic responsivity J Clin Endocrinol Metab 84 2238 2240 10372738 1:CAS:528:DyaK1MXjs1Ohtrk%3D 10.1210/jc.84.6.2238 Dinan TG, Lavelle E, Scott LV, Newell-Price J, Medbak S, Grossman AB (1999) Desmopressin normalizes the blunted adrenocorticotropin response to corticotropin-releasing hormone in melancholic depression: evidence of enhanced vasopressinergic responsivity. J Clin Endocrinol Metab 84:2238–2240
86. 86. MH Whitnall D Smyth H Gainer 1987 Vasopressin coexists in half of the corticotropin-releasing factor axons present in the external zone of the median eminence in normal rats Neuroendocrinology 45 420 424 3295576 1:STN:280:DyaL2s3ivFelsg%3D%3D 10.1159/000124768 Whitnall MH, Smyth D, Gainer H (1987) Vasopressin coexists in half of the corticotropin-releasing factor axons present in the external zone of the median eminence in normal rats. Neuroendocrinology 45:420–424
87. 87. C Rabadan-Diehl SJ Lolait G Aguilera 1995 Regulation of pituitary vasopressin V 1b receptor mRNA during stress in the rat J Neuroendocrinol 7 903 910 8745267 1:CAS:528:DyaK28XnsV2msQ%3D%3D 10.1111/j.1365-2826.1995.tb00734.x Rabadan-Diehl C, Lolait SJ, Aguilera G (1995) Regulation of pituitary vasopressin V 1b receptor mRNA during stress in the rat. J Neuroendocrinol 7:903–910
88. 88. MH Whitnall 1989 Stress selectively activates the vasopressin-containing subset of corticotropin-releasing hormone neurons Neuroendocrinology 50 702 707 2515467 1:CAS:528:DyaK3cXjtVyrsA%3D%3D 10.1159/000125302 Whitnall MH (1989) Stress selectively activates the vasopressin-containing subset of corticotropin-releasing hormone neurons. Neuroendocrinology 50:702–707
89. 89. AB Abou-Samra KJ Catt G Aguilera 1986 Biphasic inhibition of adrenocorticotropin release by corticosterone in cultured anterior pituitary cells Endocrinology 119 972 977 3015577 1:CAS:528:DyaL28Xlt1OktL4%3D 10.1210/endo-119-3-972 Abou-Samra AB, Catt KJ, Aguilera G (1986) Biphasic inhibition of adrenocorticotropin release by corticosterone in cultured anterior pituitary cells. Endocrinology 119:972–977
90. 90. LM Bilezikjian AL Blount WW Vale 1987 The cellular actions of vasopressin on corticotrophs of the anterior pituitary: resistance to glucocorticoid action Mol Endocrinol 1 451 458 3153472 1:CAS:528:DyaL2sXmt12ms7c%3D 10.1210/mend-1-7-451 Bilezikjian LM, Blount AL, Vale WW (1987) The cellular actions of vasopressin on corticotrophs of the anterior pituitary: resistance to glucocorticoid action. Mol Endocrinol 1:451–458
91. 91. ME Keck A Wigger T Welt MB Muller A Gesing JM Reul F Holsboer R Landgraf ID Neumann 2002 Vasopressin mediates the response of the combined dexamethasone/CRH test in hyper-anxious rats: implications for pathogenesis of affective disorders Neuropsychopharmacology 26 94 105 11751036 1:CAS:528:DC%2BD3MXpt1antbY%3D 10.1016/S0893-133X(01)00351-7 Keck ME, Wigger A, Welt T, Muller MB, Gesing A, Reul JM, Holsboer F, Landgraf R, Neumann ID (2002) Vasopressin mediates the response of the combined dexamethasone/CRH test in hyper-anxious rats: implications for pathogenesis of affective disorders. Neuropsychopharmacology 26:94–105
92. 92. R Landgraf A Wigger F Holsboer ID Neumann 1999 Hyper-reactive hypothalamo-pituitary-adrenocortical axis in rats bred for high anxiety-related behaviour J Neuroendocrinol 11 405 407 10336720 1:CAS:528:DyaK1MXjs1yhu7s%3D 10.1046/j.1365-2826.1999.00342.x Landgraf R, Wigger A, Holsboer F, Neumann ID (1999) Hyper-reactive hypothalamo-pituitary-adrenocortical axis in rats bred for high anxiety-related behaviour. J Neuroendocrinol 11:405–407
93. 93. N Salome J Stemmelin C Cohen G Griebel 2006 Differential roles of amygdaloid nuclei in the anxiolytic-and antidepressant-like effects of the V 1b receptor antagonist, SSR149415, in rats Psychopharmacology 187 237 244 16779555 1:CAS:528:DC%2BD28Xms1Gqur0%3D 10.1007/s00213-006-0424-1 Salome N, Stemmelin J, Cohen C, Griebel G (2006) Differential roles of amygdaloid nuclei in the anxiolytic-and antidepressant-like effects of the V 1b receptor antagonist, SSR149415, in rats. Psychopharmacology 187:237–244
94. 94. C Murgatroyd A Wigger E Frank N Singewald M Bunck F Holsboer R Landgraf D Spengler 2004 Impaired repression at a vasopressin promoter polymorphism underlies overexpression of vasopressin in a rat model of trait anxiety J Neurosci 24 7762 7770 15342744 1:CAS:528:DC%2BD2cXns1Oqtrg%3D 10.1523/JNEUROSCI.1614-04.2004 Murgatroyd C, Wigger A, Frank E, Singewald N, Bunck M, Holsboer F, Landgraf R, Spengler D (2004) Impaired repression at a vasopressin promoter polymorphism underlies overexpression of vasopressin in a rat model of trait anxiety. J Neurosci 24:7762–7770
95. 95. A Wigger MM Sanchez KC Mathys K Ebner E Frank D Liu A Kresse ID Neumann F Holsboer PM Plotsky R Landgraf 2004 Alterations in central neuropeptide expression, release, and receptor binding in rats bred for high anxiety: critical role of vasopressin Neuropsychopharmacology 29 1 14 12942143 1:CAS:528:DC%2BD3sXhtVSqs7nO 10.1038/sj.npp.1300290 Wigger A, Sanchez MM, Mathys KC, Ebner K, Frank E, Liu D, Kresse A, Neumann ID, Holsboer F, Plotsky PM, Landgraf R (2004) Alterations in central neuropeptide expression, release, and receptor binding in rats bred for high anxiety: critical role of vasopressin. Neuropsychopharmacology 29:1–14
96. 96. ME Keck T Welt MB Muller M Uhr F Ohl A Wigger N Toschi F Holsboer R Landgraf 2003 Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model Neuropsychopharmacology 28 235 243 12589376 1:CAS:528:DC%2BD3sXhtFGhtrg%3D 10.1038/sj.npp.1300040 Keck ME, Welt T, Muller MB, Uhr M, Ohl F, Wigger A, Toschi N, Holsboer F, Landgraf R (2003) Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmacology 28:235–243
97. 97. R Landgraf 2006 The involvement of the vasopressin system in stress-related disorders CNS Neurol Disord Drug Targets 5 167 179 16611090 1:CAS:528:DC%2BD28XktlCnt7c%3D 10.2174/187152706776359664 Landgraf R (2006) The involvement of the vasopressin system in stress-related disorders. CNS Neurol Disord Drug Targets 5:167–179
98. 98. AR Caffe FW Leeuwen van PG Luiten 1987 Vasopressin cells in the medial amygdala of the rat project to the lateral septum and ventral hippocampus J Comp Neurol 261 237 252 3305600 1:STN:280:DyaL2szgvV2lsA%3D%3D 10.1002/cne.902610206 Caffe AR, van Leeuwen FW, Luiten PG (1987) Vasopressin cells in the medial amygdala of the rat project to the lateral septum and ventral hippocampus. J Comp Neurol 261:237–252
99. 99. GJ Vries De RM Buijs 1983 The origin of the vasopressinergic and oxytocinergic innervation of the rat brain with special reference to the lateral septum Brain Res 273 307 317 6311351 10.1016/0006-8993(83)90855-7 De Vries GJ, Buijs RM (1983) The origin of the vasopressinergic and oxytocinergic innervation of the rat brain with special reference to the lateral septum. Brain Res 273:307–317
100. 100. CT Wotjak M Kubota G Liebsch A Montkowski F Holsboer I Neumann R Landgraf 1996 Release of vasopressin within the rat paraventricular nucleus in response to emotional stress: a novel mechanism of regulating adrenocorticotropic hormone secretion? J Neurosci 16 7725 7732 8922428 1:CAS:528:DyaK28XntFOisb4%3D Wotjak CT, Kubota M, Liebsch G, Montkowski A, Holsboer F, Neumann I, Landgraf R (1996) Release of vasopressin within the rat paraventricular nucleus in response to emotional stress: a novel mechanism of regulating adrenocorticotropic hormone secretion?. J Neurosci 16:7725–7732
101. 101. K Ebner CT Wotjak R Landgraf M Engelmann 2000 A single social defeat experience selectively stimulates the release of oxytocin, but not vasopressin, within the septal brain area of male rats Brain Res 872 87 92 10924679 1:CAS:528:DC%2BD3cXltlektrc%3D 10.1016/S0006-8993(00)02464-1 Ebner K, Wotjak CT, Landgraf R, Engelmann M (2000) A single social defeat experience selectively stimulates the release of oxytocin, but not vasopressin, within the septal brain area of male rats. Brain Res 872:87–92
102. 102. K Ebner CT Wotjak F Holsboer M Engelmann 1999 Vasopressin released within the septal brain area during swim stress modulates the behavioural stress response in rats Eur J Neurosci 11 997 1002 10103093 1:STN:280:DyaK1M3gtlehtA%3D%3D 10.1046/j.1460-9568.1999.00508.x Ebner K, Wotjak CT, Holsboer F, Engelmann M (1999) Vasopressin released within the septal brain area during swim stress modulates the behavioural stress response in rats. Eur J Neurosci 11:997–1002
103. 103. CT Wotjak J Ganster G Kohl F Holsboer R Landgraf M Engelmann 1998 Dissociated central and peripheral release of vasopressin, but not oxytocin, in response to repeated swim stress: new insights into the secretory capacities of peptidergic neurons Neuroscience 85 1209 1222 9681958 1:CAS:528:DyaK1cXjvVehtbw%3D 10.1016/S0306-4522(97)00683-0 Wotjak CT, Ganster J, Kohl G, Holsboer F, Landgraf R, Engelmann M (1998) Dissociated central and peripheral release of vasopressin, but not oxytocin, in response to repeated swim stress: new insights into the secretory capacities of peptidergic neurons. Neuroscience 85:1209–1222
104. 104. F Hernando O Schoots SJ Lolait JP Burbach 2001 Immunohistochemical localization of the vasopressin V 1b receptor in the rat brain and pituitary gland: anatomical support for its involvement in the central effects of vasopressin Endocrinology 142 1659 1668 11250948 1:CAS:528:DC%2BD3MXitlelsr8%3D 10.1210/en.142.4.1659 Hernando F, Schoots O, Lolait SJ, Burbach JP (2001) Immunohistochemical localization of the vasopressin V 1b receptor in the rat brain and pituitary gland: anatomical support for its involvement in the central effects of vasopressin. Endocrinology 142:1659–1668
105. 105. WS Young J Li SR Wersinger M Palkovits 2006 The vasopressin 1b receptor is prominent in the hippocampal area CA2 where it is unaffected by restraint stress or adrenalectomy Neuroscience 143 1031 1039 17027167 1:CAS:528:DC%2BD28Xht1KgurnE 10.1016/j.neuroscience.2006.08.040 Young WS, Li J, Wersinger SR, Palkovits M (2006) The vasopressin 1b receptor is prominent in the hippocampal area CA2 where it is unaffected by restraint stress or adrenalectomy. Neuroscience 143:1031–1039
106. 106. SR Wersinger EI Ginns AM O’Carroll SJ Lolait WS Young III 2002 Vasopressin V1b receptor knockout reduces aggressive behavior in male mice Mol Psychiatry 7 975 984 12399951 1:CAS:528:DC%2BD38XotFWrtr0%3D 10.1038/sj.mp.4001195 Wersinger SR, Ginns EI, O’Carroll AM, Lolait SJ, Young WS III (2002) Vasopressin V1b receptor knockout reduces aggressive behavior in male mice. Mol Psychiatry 7:975–984
107. 107. S Itoh S Yamada T Mori T Miwa K Tottori Y Uwahodo Y Yamamura M Fukuda K Yamamoto A Tanoue G Tsujimoto 2006 Attenuated stress-induced catecholamine release in mice lacking the vasopressin V1b receptor Am J Physiol Endocrinol Metab 291 E147 E151 16464910 1:CAS:528:DC%2BD28XntFGitrg%3D 10.1152/ajpendo.00005.2006 Itoh S, Yamada S, Mori T, Miwa T, Tottori K, Uwahodo Y, Yamamura Y, Fukuda M, Yamamoto K, Tanoue A, Tsujimoto G (2006) Attenuated stress-induced catecholamine release in mice lacking the vasopressin V1b receptor. Am J Physiol Endocrinol Metab 291:E147–E151
108. 108. SR Wersinger KR Kelliher F Zufall SJ Lolait AM O’Carroll WS Young III 2004 Social motivation is reduced in vasopressin 1b receptor null mice despite normal performance in an olfactory discrimination task Horm Behav 46 638 645 15555506 1:CAS:528:DC%2BD2cXpsl2hsLw%3D 10.1016/j.yhbeh.2004.07.004 Wersinger SR, Kelliher KR, Zufall F, Lolait SJ, O’Carroll AM, Young WS III (2004) Social motivation is reduced in vasopressin 1b receptor null mice despite normal performance in an olfactory discrimination task. Horm Behav 46:638–645
109. 109. A Tanoue S Ito K Honda S Oshikawa Y Kitagawa TA Koshimizu T Mori G Tsujimoto 2004 The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions J Clin Invest 113 302 309 14722621 1:CAS:528:DC%2BD2cXmsVyqtg%3D%3D Tanoue A, Ito S, Honda K, Oshikawa S, Kitagawa Y, Koshimizu TA, Mori T, Tsujimoto G (2004) The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J Clin Invest 113:302–309
110. 110. SJ Lolait LQ Stewart DS Jessop WS Young III AM O’Carroll 2007 The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors Endocrinology 148 849 856 17122081 1:CAS:528:DC%2BD2sXhtlOjtbg%3D 10.1210/en.2006-1309 Lolait SJ, Stewart LQ, Jessop DS, Young WS III, O’Carroll AM (2007) The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors. Endocrinology 148:849–856
111. 111. S Het G Ramlow OT Wolf 2005 A meta-analytic review of the effects of acute cortisol administration on human memory Psychoneuroendocrinology 30 771 784 15919583 1:CAS:528:DC%2BD2MXks1aktL4%3D 10.1016/j.psyneuen.2005.03.005 Het S, Ramlow G, Wolf OT (2005) A meta-analytic review of the effects of acute cortisol administration on human memory. Psychoneuroendocrinology 30:771–784
112. 112. C Roozendaal 2002 Stress and memory: opposing effects of glucocorticoids on memory consolidation and memory retrieval Neurobiol Learn Mem 78 578 595 12559837 1:CAS:528:DC%2BD3sXht12mtg%3D%3D 10.1006/nlme.2002.4080 Roozendaal C (2002) Stress and memory: opposing effects of glucocorticoids on memory consolidation and memory retrieval. Neurobiol Learn Mem 78:578–595
113. 113. MN Starkman C Giordani S Berent MA Schork DE Schteingart 2001 Elevated cortisol levels in Cushing’s. disease are associated with cognitive decrements Psychosom Med 63 985 993 11719638 1:STN:280:DC%2BD3MnntlOltQ%3D%3D Starkman MN, Giordani C, Berent S, Schork MA, Schteingart DE (2001) Elevated cortisol levels in Cushing’s. disease are associated with cognitive decrements. Psychosom Med 63:985–993
114. 114. N Sonino GA Fava 2001 Psychiatric disorders associated with Cushing’s. syndrome. Epidemiology, pathophysiology and treatment CNS Drugs 15 361 373 11475942 1:CAS:528:DC%2BD3MXkt1OlsL4%3D 10.2165/00023210-200115050-00003 Sonino N, Fava GA (2001) Psychiatric disorders associated with Cushing’s. syndrome. Epidemiology, pathophysiology and treatment. CNS Drugs 15:361–373
115. 115. LD Dorn ES Burgess TC Friedman B Dubbert PW Gold GP Chrousos 1997 The longitudinal course of psychopathology in Cushing’s. syndrome after correction of hypercortisolism J Clin Endocrinol Metab 82 912 919 9062506 1:CAS:528:DyaK2sXhsl2htbw%3D 10.1210/jc.82.3.912 Dorn LD, Burgess ES, Friedman TC, Dubbert B, Gold PW, Chrousos GP (1997) The longitudinal course of psychopathology in Cushing’s. syndrome after correction of hypercortisolism. J Clin Endocrinol Metab 82:912–919
116. 116. YI Sheline PW Wang MH Gado JG Csernansky MW Vannier 1996 Hippocampal atrophy in recurrent major depression Proc Natl Acad Sci USA 93 3908 3913 8632988 1:CAS:528:DyaK28XivVKrt7k%3D 10.1073/pnas.93.9.3908 Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW (1996) Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 93:3908–3913
117. 117. MN Starkman SS Gebarski S Berent 1992 Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing’s. syndrome Biol Psychiatry 32 9 756 765 1450290 1:STN:280:DyaK3s%2FotFKhsg%3D%3D 10.1016/0006-3223(92)90079-F Starkman MN, Gebarski SS, Berent S et al (1992) Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing’s. syndrome. Biol Psychiatry 32(9):756–765
118. 118. MN Starkman C Giordani SS Gebarski S Berent MA Schork DE Schteingart 1999 Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing’s. disease Biol Psychiatry 46 1595 1602 10624540 1:CAS:528:DC%2BD3cXnvF2j 10.1016/S0006-3223(99)00203-6 Starkman MN, Giordani C, Gebarski SS, Berent S, Schork MA, Schteingart DE (1999) Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing’s. disease. Biol Psychiatry 46:1595–1602
119. 119. E Gould P Tanapat 1999 Stress and hippocampal neurogenesis Biol Psychiatry 46 1472 1479 10599477 1:STN:280:DC%2BD3c%2FmslGrtg%3D%3D 10.1016/S0006-3223(99)00247-4 Gould E, Tanapat P (1999) Stress and hippocampal neurogenesis. Biol Psychiatry 46:1472–1479
120. 120. N Sousa MD Madeira MM Paula-Barbosa 1998 Effects of corticosterone treatment and rehabilitation on the hippocampal formation of neonatal and adult rats. An unbiased stereological study Brain Res 794 199 210 9622630 1:CAS:528:DyaK1cXjsVehsLo%3D 10.1016/S0006-8993(98)00218-2 Sousa N, Madeira MD, Paula-Barbosa MM (1998) Effects of corticosterone treatment and rehabilitation on the hippocampal formation of neonatal and adult rats. An unbiased stereological study. Brain Res 794:199–210
121. 121. H Chen GN Pandey Y Dwivedi 2006 Hippocampal cell proliferation regulation by repeated stress and antidepressants Neuroreport 17 863 867 16738477 10.1097/01.wnr.0000221827.03222.70 Chen H, Pandey GN, Dwivedi Y (2006) Hippocampal cell proliferation regulation by repeated stress and antidepressants. Neuroreport 17:863–867
122. 122. E Fuchs G Flugge F Ohl P Lucassen GK Vollmann-Honsdorf T Michaelis 2001 Psychosocial stress, glucocorticoids, and structural alterations in the tree shrew hippocampus Physiol Behav 73 285 291 11438353 1:CAS:528:DC%2BD3MXkvVelurk%3D 10.1016/S0031-9384(01)00497-8 Fuchs E, Flugge G, Ohl F, Lucassen P, Vollmann-Honsdorf GK, Michaelis T (2001) Psychosocial stress, glucocorticoids, and structural alterations in the tree shrew hippocampus. Physiol Behav 73:285–291
123. 123. MF Montaron E Drapeau D Dupret P Kitchener C Aurousseau M Moal Le PV Piazza DN Abrous 2006 Lifelong corticosterone level determines age-related decline in neurogenesis and memory Neurobiol Aging 27 645 654 15953661 1:CAS:528:DC%2BD28XitVClt7o%3D 10.1016/j.neurobiolaging.2005.02.014 Montaron MF, Drapeau E, Dupret D, Kitchener P, Aurousseau C, Le Moal M, Piazza PV, Abrous DN (2006) Lifelong corticosterone level determines age-related decline in neurogenesis and memory. Neurobiol Aging 27:645–654
124. 124. C Crochemore J Lu Y Wu Z Liposits N Sousa F Holsboer OF Almeida 2005 Direct targeting of hippocampal neurons for apoptosis by glucocorticoids is reversible by mineralocorticoid receptor activation Mol Psychiatry 10 790 798 15940303 1:CAS:528:DC%2BD2MXmsFWmsbo%3D 10.1038/sj.mp.4001679 Crochemore C, Lu J, Wu Y, Liposits Z, Sousa N, Holsboer F, Almeida OF (2005) Direct targeting of hippocampal neurons for apoptosis by glucocorticoids is reversible by mineralocorticoid receptor activation. Mol Psychiatry 10:790–798
125. 125. CM Pariante SA Thomas S Lovestone A Makoof RW Kerwin 2004 Do antidpressants regulate how cortisol affects the brain? Psychoneuroendocrinology 29 423 447 14749091 1:CAS:528:DC%2BD2cXmvFKnsw%3D%3D 10.1016/j.psyneuen.2003.10.009 Pariante CM, Thomas SA, Lovestone S, Makoof A, Kerwin RW (2004) Do antidpressants regulate how cortisol affects the brain? Psychoneuroendocrinology 29:423–447
126. 126. AM Karssen OC Meijer IC Sandt van der PJ Lucassen EC Lange de AG Boer de ER Kloet de 2001 Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain Endocrinology 142 2686 2694 11356720 1:CAS:528:DC%2BD3MXjvFGnsbk%3D 10.1210/en.142.6.2686 Karssen AM, Meijer OC, van der Sandt IC, Lucassen PJ, de Lange EC, de Boer AG, de Kloet ER (2001) Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology 142:2686–2694
127. 127. AH Schinkel 1999 P-Glycoprotein, a gatekeeper in the blood–brain barrier Adv Drug Deliv Rev 36 179 194 10837715 1:CAS:528:DyaK1MXhvVCgu7Y%3D 10.1016/S0169-409X(98)00085-4 Schinkel AH (1999) P-Glycoprotein, a gatekeeper in the blood–brain barrier. Adv Drug Deliv Rev 36:179–194
128. 128. CM Pariante RB Kim A Makoff RW Kerwin 2003 Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters Br J Pharmacol 139 1111 1118 12871829 1:CAS:528:DC%2BD3sXmtFemt7g%3D 10.1038/sj.bjp.0705357 Pariante CM, Kim RB, Makoff A, Kerwin RW (2003) Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. Br J Pharmacol 139:1111–1118
129. 129. CM Pariante A Hye R Williamson A Makoff S Lovestone RW Kerwin 2003 The antidepressant clomipramine regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones Neuropsychopharmacology 28 1553 1561 12784111 1:CAS:528:DC%2BD3sXmsFeis70%3D 10.1038/sj.npp.1300195 Pariante CM, Hye A, Williamson R, Makoff A, Lovestone S, Kerwin RW (2003) The antidepressant clomipramine regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones. Neuropsychopharmacology 28:1553–1561
130. 130. E Holsboer-Trachsler R Stohler M Hatzinger 1991 Repeated administration of the combined dexamethasone-human corticotropin releasing hormone stimulation test during treatment of depression Psychiatry Res 38 163 171 1661430 1:CAS:528:DyaK38XptV0%3D 10.1016/0165-1781(91)90041-M Holsboer-Trachsler E, Stohler R, Hatzinger M (1991) Repeated administration of the combined dexamethasone-human corticotropin releasing hormone stimulation test during treatment of depression. Psychiatry Res 38:163–171
131. 131. BE Murphy 1997 Antiglucocorticoid therapies in major depression: a review Psychoneuroendocrinology 22 S125 S132 9264159 10.1016/S0306-4530(97)00021-8 Murphy BE (1997) Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology 22:S125–S132
132. 132. BE Murphy 1991 Treatment of major depression with steroid suppressive drugs J Steroid Biochem Mol Biol 39 239 244 1888684 1:CAS:528:DyaK3MXmt1egtrc%3D 10.1016/0960-0760(91)90069-H Murphy BE (1991) Treatment of major depression with steroid suppressive drugs. J Steroid Biochem Mol Biol 39:239–244
133. 133. BE Murphy AM Ghadirian V Dhar 1998 Neuroendocrine responses to inhibitors of steroid biosynthesis in patients with major depression resistant to antidepressant therapy Can J Psychiatry 43 279 286 9561317 1:STN:280:DyaK1c3it1Sqsg%3D%3D Murphy BE, Ghadirian AM, Dhar V (1998) Neuroendocrine responses to inhibitors of steroid biosynthesis in patients with major depression resistant to antidepressant therapy. Can J Psychiatry 43:279–286
134. 134. AM O’Dwyer SL Lightman MN Marks SA Checkley 1995 Treatment of major depression with metyrapone and hydrocortisone J Affect Disord 33 123 128 7759660 1:STN:280:ByqB2sbls10%3D 10.1016/0165-0327(94)00082-K O’Dwyer AM, Lightman SL, Marks MN, Checkley SA (1995) Treatment of major depression with metyrapone and hydrocortisone. J Affect Disord 33:123–128
135. 135. JH Thakore TG Dinan 1995 Cortisol synthesis inhibition: a new treatment strategy for the clinical and endocrine manifestations of depression Biol Psychiatry 37 364 368 7772644 1:STN:280:DyaK2M3ptVGnug%3D%3D 10.1016/0006-3223(94)00137-R Thakore JH, Dinan TG (1995) Cortisol synthesis inhibition: a new treatment strategy for the clinical and endocrine manifestations of depression. Biol Psychiatry 37:364–368
136. 136. OM Wolkowitz VI Reus F Manfredi J Ingbar L Brizendine H Weingartner 1993 Ketoconazole administration in hypercortisolemic depression Am J Psychiatry 150 810 812 8480829 1:STN:280:DyaK3s3ktlClug%3D%3D Wolkowitz OM, Reus VI, Manfredi F, Ingbar J, Brizendine L, Weingartner H (1993) Ketoconazole administration in hypercortisolemic depression. Am J Psychiatry 150:810–812
137. 137. H Cohen J Benjamin Z Kaplan M Kotler 2000 Administration of high-dose ketoconazole, an inhibitor of steroid synthesis, prevents posttraumatic anxiety in an animal model Eur Neuropsychopharmacol 10 429 435 11115731 1:CAS:528:DC%2BD3cXoslGjtro%3D 10.1016/S0924-977X(00)00105-X Cohen H, Benjamin J, Kaplan Z, Kotler M (2000) Administration of high-dose ketoconazole, an inhibitor of steroid synthesis, prevents posttraumatic anxiety in an animal model. Eur Neuropsychopharmacol 10:429–435
138. 138. GA Kennett SL Dickinson G Curzon 1985 Central serotonergic responses and behavioural adaptation to repeated immobilisation: the effect of the corticosterone synthesis inhibitor metyrapone Eur J Pharmacol 119 143 152 4092729 1:CAS:528:DyaL28XhtVagsb0%3D 10.1016/0014-2999(85)90290-0 Kennett GA, Dickinson SL, Curzon G (1985) Central serotonergic responses and behavioural adaptation to repeated immobilisation: the effect of the corticosterone synthesis inhibitor metyrapone. Eur J Pharmacol 119:143–152
139. 139. Z Rogoz C Budziszewska M Kubera A Basta-Kaim L Jaworska-Feil G Skuza W Lason 2005 Effect of combined treatment with imipramine and metyrapone on the immobility time, the activity of hypothalamo-pituitary-adrenocortical axis and immunological parameters in the forced swimming test in the rat J Physiol Pharmacol 56 49 61 15795475 1:CAS:528:DC%2BD2MXjtleluro%3D Rogoz Z, Budziszewska C, Kubera M, Basta-Kaim A, Jaworska-Feil L, Skuza G, Lason W (2005) Effect of combined treatment with imipramine and metyrapone on the immobility time, the activity of hypothalamo-pituitary-adrenocortical axis and immunological parameters in the forced swimming test in the rat. J Physiol Pharmacol 56:49–61
140. 140. H Jahn M Schick F Kiefer M Kellner A Yassouridis K Wiedemann 2004 Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial Arch Gen Psychiatry 61 1235 1244 15583115 1:CAS:528:DC%2BD2MXjt1Kmtg%3D%3D 10.1001/archpsyc.61.12.1235 Jahn H, Schick M, Kiefer F, Kellner M, Yassouridis A, Wiedemann K (2004) Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry 61:1235–1244
141. 141. PC White PW Speiser 1994 Steroid 11 beta-hydroxylase deficiency and related disorders Endocrinol Metab Clin North Am 23 325 339 8070425 1:CAS:528:DyaK2cXmtVWrtL8%3D White PC, Speiser PW (1994) Steroid 11 beta-hydroxylase deficiency and related disorders. Endocrinol Metab Clin North Am 23:325–339
142. 142. M Craighead S Macdonald A Hilier M Speake F Thomson Z Turnbull L Watson 2004 Org 34850 is a potent antagonist of the glucorticoid receptor, in vivo and in vitro J Affect Disord 78 S107 Craighead M, Macdonald S, Hilier A, Speake M, Thomson F, Turnbull Z, Watson L (2004) Org 34850 is a potent antagonist of the glucorticoid receptor, in vivo and in vitro. J Affect Disord 78:S107
143. 143. F Thomson C Broekkamp M Craighead S Eason A Hilier C Peeters M Speake L Watson 2004 In vivo and in vitro charterisation of the glucocorticoid receptor antagonist Org 34517 J Affect Disord 78 S138 Thomson F, Broekkamp C, Craighead M, Eason S, Hilier A, Peeters C, Speake M, Watson L (2004) In vivo and in vitro charterisation of the glucocorticoid receptor antagonist Org 34517. J Affect Disord 78:S138
144. 144. JL Mayer L Klumpers S Maslam ER Kloet de M Joels PJ Lucassen 2006 Brief treatment with the glucocorticoid receptor antagonist mifepristone normalises the corticosterone-induced reduction of adult hippocampal neurogenesis J Neuroendocrinol 18 629 631 16867184 1:CAS:528:DC%2BD28XosVKnt7s%3D 10.1111/j.1365-2826.2006.01455.x Mayer JL, Klumpers L, Maslam S, de Kloet ER, Joels M, Lucassen PJ (2006) Brief treatment with the glucocorticoid receptor antagonist mifepristone normalises the corticosterone-induced reduction of adult hippocampal neurogenesis. J Neuroendocrinol 18:629–631
145. 145. Spiga F, Harrison LR, Wood SA, Atkinson HC, MacSweeney C, Lightman SL (2006) Sub-chronic treatment with the glucocorticoid receptor antagonist Org 34850 increases basal HPA axis activity in rats. ISPNE Congress 2006, Leiden, The Netherlands
146. 146. CG Bachmann AC Linthorst F Holsboer JM Reul 2003 Effect of chronic administration of selective glucocorticoid receptor antagonists on the rat hypothalamic-pituitary-adrenocortical axis Neuropsychopharmacology 28 1056 1067 12700716 1:CAS:528:DC%2BD3sXjvF2ltbg%3D Bachmann CG, Linthorst AC, Holsboer F, Reul JM (2003) Effect of chronic administration of selective glucocorticoid receptor antagonists on the rat hypothalamic-pituitary-adrenocortical axis. Neuropsychopharmacology 28:1056–1067
147. 147. ER Kloet de S Kock De V Schild HD Veldhuis 1988 Antiglucocorticoid RU 38486 attenuates retention of a behaviour and disinhibits the hypothalamic-pituitary adrenal axis at different brain sites Neuroendocrinology 47 109 115 3344063 10.1159/000124900 de Kloet ER, De Kock S, Schild V, Veldhuis HD (1988) Antiglucocorticoid RU 38486 attenuates retention of a behaviour and disinhibits the hypothalamic-pituitary adrenal axis at different brain sites. Neuroendocrinology 47:109–115
148. 148. A Bilang-Bleuel S Ulbricht Y Chandramohan S Carli De SK Droste JM Reul 2005 Psychological stress increases histone H3 phosphorylation in adult dentate gyrus granule neurons: involvement in a glucocorticoid receptor-dependent behavioural response Eur J Neurosci 22 1691 1700 16197509 10.1111/j.1460-9568.2005.04358.x Bilang-Bleuel A, Ulbricht S, Chandramohan Y, De Carli S, Droste SK, Reul JM (2005) Psychological stress increases histone H3 phosphorylation in adult dentate gyrus granule neurons: involvement in a glucocorticoid receptor-dependent behavioural response. Eur J Neurosci 22:1691–1700
149. 149. Smith LH, Erdemli G, Grassie M (2005) Central action of glucocorticoid receptor antagonists. ISPNE Congress 2005, Montreal, Canada
150. 150. Smith LH, Erdemli G, Grassie M (2005) Central action of glucocorticoid receptor antagonists. BAP Congress 2005, Harrogate, UK
151. 151. AJ Lely van der K Foeken RC Mast van der SW Lamberts 1991 Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486) Ann Intern Med 114 143 144 1984391 van der Lely AJ, Foeken K, van der Mast RC, Lamberts SW (1991) Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486). Ann Intern Med 114:143–144
152. 152. OJ Hoyberg G Wijk OP Mehtonen BWMM Peeters C Senneff 2002 Org 34517, a selective glucocorticoid receptor antagonist with potent antidepressant activity: First clinical results Int J Neuropsychopharmacol 5 S148 Hoyberg OJ, Wijk G, Mehtonen OP, Peeters BWMM, Senneff C (2002) Org 34517, a selective glucocorticoid receptor antagonist with potent antidepressant activity: First clinical results. Int J Neuropsychopharmacol 5:S148
153. 153. JK Belanoff BH Flores M Kalezhan B Sund AF Schatzberg 2001 Rapid reversal of psychotic depression using mifepristone J Clin Psychopharmacol 21 516 521 11593077 1:CAS:528:DC%2BD3MXnslSlsr0%3D 10.1097/00004714-200110000-00009 Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF (2001) Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol 21:516–521
154. 154. C DeBattista J Belanoff S Glass A Khan RL Horne C Blasey LL Carpenter G Alva 2006 Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression Biol Psychiatry 60 1343 1349 16889757 1:CAS:528:DC%2BD28Xht12kt7rP 10.1016/j.biopsych.2006.05.034 DeBattista C, Belanoff J, Glass S, Khan A, Horne RL, Blasey C, Carpenter LL, Alva G (2006) Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol Psychiatry 60:1343–1349
155. 155. AH Young P Gallagher S Watson D Estal Del BM Owen IN Ferrier 2004 Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder Neuropsychopharmacology 29 1538 1545 15127079 1:CAS:528:DC%2BD2cXlvVSjtrs%3D 10.1038/sj.npp.1300471 Young AH, Gallagher P, Watson S, Del Estal D, Owen BM, Ferrier IN (2004) Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 29:1538–1545
156. 156. P Gallagher S Watson MS Smith IN Ferrier AH Young 2005 Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia Biol Psychiatry 57 155 161 15652874 1:CAS:528:DC%2BD2MXkvFajtQ%3D%3D 10.1016/j.biopsych.2004.10.017 Gallagher P, Watson S, Smith MS, Ferrier IN, Young AH (2005) Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia. Biol Psychiatry 57:155–161
157. 157. L Laue MT Lotze GP Chrousos K Barnes DL Loriaux TA Fleisher 1990 Effect of chronic treatment with the glucocorticoid antagonist RU 486 in man: toxicity, immunological, and hormonal aspects J Clin Endocrinol Metab 71 1474 1480 2172280 1:CAS:528:DyaK3MXhslyms7s%3D 10.1210/jcem-71-6-1474 Laue L, Lotze MT, Chrousos GP, Barnes K, Loriaux DL, Fleisher TA (1990) Effect of chronic treatment with the glucocorticoid antagonist RU 486 in man: toxicity, immunological, and hormonal aspects J Clin Endocrinol Metab 71:1474–1480
158. 158. EP Zorrilla GF Koob 2004 The therapeutic potential of CRF1 antagonists for anxiety Expert Opin Investig Drugs 13 799 828 15212620 1:CAS:528:DC%2BD2cXltVOgu78%3D 10.1517/13543784.13.7.799 Zorrilla EP, Koob GF (2004) The therapeutic potential of CRF1 antagonists for anxiety. Expert Opin Investig Drugs 13:799–828
159. 159. DM Nielsen GJ Carey LH Gold 2004 Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice Eur J Pharmacol 499 135 146 15363960 1:CAS:528:DC%2BD2cXnsFSqu78%3D 10.1016/j.ejphar.2004.07.091 Nielsen DM, Carey GJ, Gold LH (2004) Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice. Eur J Pharmacol 499:135–146
160. 160. Alonso R, Griebel G, Pavone G, Stemmelin J, Le Fur G, Soubrie P (2004) Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Mol Psychiatry 9:278–286, 224
161. 161. ME Keck T Welt A Wigger U Renner M Engelmann F Holsboer R Landgraf 2001 The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats Eur J Neurosci 13 373 380 11168542 1:STN:280:DC%2BD3M3ktl2msw%3D%3D 10.1046/j.0953-816X.2000.01383.x Keck ME, Welt T, Wigger A, Renner U, Engelmann M, Holsboer F, Landgraf R (2001) The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats. Eur J Neurosci 13:373–380
162. 162. DA Gutman MJ Owens KH Skelton KV Thrivikraman CB Nemeroff 2003 The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress J Pharmacol Exp Ther 304 874 880 12538845 1:CAS:528:DC%2BD3sXpvVCksw%3D%3D 10.1124/jpet.102.042788 Gutman DA, Owens MJ, Skelton KH, Thrivikraman KV, Nemeroff CB (2003) The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress. J Pharmacol Exp Ther 304:874–880
163. 163. A Post F Ohl OF Almeida EB Binder M Rucker S Welt E Binder F Holsboer I Sillaber 2005 Identification of molecules potentially involved in mediating the in vivo actions of the corticotropin-releasing hormone receptor 1 antagonist, NBI30775 (R121919) Psychopharmacology 180 150 158 15682302 1:CAS:528:DC%2BD2MXksVGjsb4%3D 10.1007/s00213-004-2134-x Post A, Ohl F, Almeida OF, Binder EB, Rucker M, Welt S, Binder E, Holsboer F, Sillaber I (2005) Identification of molecules potentially involved in mediating the in vivo actions of the corticotropin-releasing hormone receptor 1 antagonist, NBI30775 (R121919). Psychopharmacology 180:150–158
164. 164. AL Curtis SM Lechner LA Pavcovich RJ Valentino 1997 Activation of the locus coeruleus noradrenergic system by intracoerulear microinfusion of corticotropin-releasing factor: effects on discharge rate, cortical norepinephrine levels and cortical electroencephalographic activity J Pharmacol Exp Ther 281 163 172 9103494 1:CAS:528:DyaK2sXislSrtbo%3D Curtis AL, Lechner SM, Pavcovich LA, Valentino RJ (1997) Activation of the locus coeruleus noradrenergic system by intracoerulear microinfusion of corticotropin-releasing factor: effects on discharge rate, cortical norepinephrine levels and cortical electroencephalographic activity. J Pharmacol Exp Ther 281:163–172
165. 165. F Lejeune MJ Millan 2003 The CRF1 receptor antagonist, DMP695, abolishes activation of locus coeruleus noradrenergic neurones by CRF in anesthetized rats Eur J Pharmacol 464 127 133 12620504 1:CAS:528:DC%2BD3sXhs1Cks70%3D 10.1016/S0014-2999(03)01383-9 Lejeune F, Millan MJ (2003) The CRF1 receptor antagonist, DMP695, abolishes activation of locus coeruleus noradrenergic neurones by CRF in anesthetized rats. Eur J Pharmacol 464:127–133
166. 166. DW Schulz RS Mansbach J Sprouse JP Braselton J Collins M Corman A Dunaiskis S Faraci AW Schmidt T Seeger P Seymour FD Tingley III EN Winston YL Chen J Heym 1996 CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors Proc Natl Acad Sci USA 93 10477 10482 8816826 1:CAS:528:DyaK28XlslGrs74%3D 10.1073/pnas.93.19.10477 Schulz DW, Mansbach RS, Sprouse J, Braselton JP, Collins J, Corman M, Dunaiskis A, Faraci S, Schmidt AW, Seeger T, Seymour P, Tingley FD III, Winston EN, Chen YL, Heym J (1996) CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci USA 93:10477–10482
167. 167. A Oshima C Flachskamm JM Reul F Holsboer AC Linthorst 2003 Altered serotonergic neurotransmission but normal hypothalamic-pituitary-adrenocortical axis activity in mice chronically treated with the corticotropin-releasing hormone receptor type 1 antagonist NBI 30775 Neuropsychopharmacology 28 2148 2159 12915860 1:CAS:528:DC%2BD3sXptFOruro%3D Oshima A, Flachskamm C, Reul JM, Holsboer F, Linthorst AC (2003) Altered serotonergic neurotransmission but normal hypothalamic-pituitary-adrenocortical axis activity in mice chronically treated with the corticotropin-releasing hormone receptor type 1 antagonist NBI 30775. Neuropsychopharmacology 28:2148–2159
168. 168. AW Zobel T Nickel HE Kunzel N Ackl A Sonntag M Ising F Holsboer 2000 Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated J Psychiatr Res 34 171 181 10867111 1:STN:280:DC%2BD3cvgsFKksg%3D%3D 10.1016/S0022-3956(00)00016-9 Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F (2000) Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34:171–181
169. 169. K Held H Kunzel M Ising DA Schmid A Zobel H Murck F Holsboer A Steiger 2004 Treatment with the CRH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression J Psychiatr Res 38 129 136 14757326 1:STN:280:DC%2BD2c%2Fls1Oksw%3D%3D 10.1016/S0022-3956(03)00076-1 Held K, Kunzel H, Ising M, Schmid DA, Zobel A, Murck H, Holsboer F, Steiger A (2004) Treatment with the CRH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression. J Psychiatr Res 38:129–136
170. 170. HE Kunzel M Ising AW Zobel T Nickel N Ackl A Sonntag F Holsboer M Uhr 2005 Treatment with a CRH-1-receptor antagonist (R121919) does not affect weight or plasma leptin concentration in patients with major depression J Psychiatr Res 39 173 177 15589565 10.1016/j.jpsychires.2004.06.006 Kunzel HE, Ising M, Zobel AW, Nickel T, Ackl N, Sonntag A, Holsboer F, Uhr M (2005) Treatment with a CRH-1-receptor antagonist (R121919) does not affect weight or plasma leptin concentration in patients with major depression. J Psychiatr Res 39:173–177
171. 171. HE Kunzel AW Zobel T Nickel N Ackl M Uhr A Sonntag M Ising F Holsboer 2003 Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects J Psychiatr Res 37 525 533 14563384 10.1016/S0022-3956(03)00070-0 Kunzel HE, Zobel AW, Nickel T, Ackl N, Uhr M, Sonntag A, Ising M, Holsboer F (2003) Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects. J Psychiatr Res 37:525–533
172. 172. G Griebel J Simiand J Stemmelin CS Gal R Steinberg 2003 The vasopressin V 1b receptor as a therapeutic target in stress-related disorders Curr Drug Targets CNS Neurol Disord 2 191 200 12769799 1:CAS:528:DC%2BD3sXks1GmsLo%3D 10.2174/1568007033482850 Griebel G, Simiand J, Stemmelin J, Gal CS, Steinberg R (2003) The vasopressin V 1b receptor as a therapeutic target in stress-related disorders. Curr Drug Targets CNS Neurol Disord 2:191–200
173. 173. C Griffante A Green O Curcuruto CP Haslam BA Dickinson R Arban 2005 Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V 1b /oxytocin receptor antagonist Br J Pharmacol 146 744 751 16158071 1:CAS:528:DC%2BD2MXhtFKht7nO 10.1038/sj.bjp.0706383 Griffante C, Green A, Curcuruto O, Haslam CP, Dickinson BA, Arban R (2005) Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V 1b /oxytocin receptor antagonist. Br J Pharmacol 146:744–751
174. 174. C Serradeil-Le Gal J Wagnon J Simiand G Griebel C Lacour G Guillon C Barberis G Brossard P Soubrie D Nisato M Pascal R Pruss B Scatton JP Maffrand G Le Fur 2002 Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N.,N.-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V 1b receptor antagonist J Pharmacol Exp Ther 300 1122 1130 11861823 1:CAS:528:DC%2BD38XitVeltrk%3D 10.1124/jpet.300.3.1122 Serradeil-Le Gal C, Wagnon J, Simiand J, Griebel G, Lacour C, Guillon G, Barberis C, Brossard G, Soubrie P, Nisato D, Pascal M, Pruss R, Scatton B, Maffrand JP, Le Fur G (2002) Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N.,N.-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V 1b receptor antagonist. J Pharmacol Exp Ther 300:1122–1130
175. 175. G Griebel J Simiand R Steinberg M Jung D Gully P Roger M Geslin B Scatton JP Maffrand P Soubrie 2002 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N.-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders J Pharmacol Exp Ther 301 333 345 11907191 1:CAS:528:DC%2BD38Xis1KqsL4%3D 10.1124/jpet.301.1.333 Griebel G, Simiand J, Steinberg R, Jung M, Gully D, Roger P, Geslin M, Scatton B, Maffrand JP, Soubrie P (2002) 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N.-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 301:333–345
176. 176. T Shimazaki M Iijima S Chaki 2006 The pituitary mediates the anxiolytic-like effects of the vasopressin V 1b receptor antagonist, SSR149415, in a social interaction test in rats Eur J Pharmacol 543 63 67 16843459 1:CAS:528:DC%2BD28XntlWlsLw%3D 10.1016/j.ejphar.2006.06.032 Shimazaki T, Iijima M, Chaki S (2006) The pituitary mediates the anxiolytic-like effects of the vasopressin V 1b receptor antagonist, SSR149415, in a social interaction test in rats. Eur J Pharmacol 543:63–67
177. 177. J Stemmelin L Lukovic N Salome G Griebel 2005 Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V 1b receptor antagonist, SSR149415 Neuropsychopharmacology 30 1 35 42 15367924 1:CAS:528:DC%2BD2cXhtVyisbvP 10.1038/sj.npp.1300562 Stemmelin J, Lukovic L, Salome N, Griebel G (2005) Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V 1b receptor antagonist, SSR149415. Neuropsychopharmacology 30(1):35–42
178. 178. G Griebel J Simiand C Serradeil-Le Gal J Wagnon M Pascal B Scatton JP Maffrand P Soubrie 2002 Anxiolytic-and antidepressant-like effects of the non-peptide vasopressin V 1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders Proc Natl Acad Sci USA 99 6370 6375 11959912 1:CAS:528:DC%2BD38XjslWnt78%3D 10.1073/pnas.092012099 Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P (2002) Anxiolytic-and antidepressant-like effects of the non-peptide vasopressin V 1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 99:6370–6375
179. 179. BJ Carroll 1982 Clinical applications of the dexamethasone supprssion test for endogenous depression Pharmacopsychiatria 15 19 25 7038718 1:STN:280:DyaL387ltFeltg%3D%3D 10.1055/s-2007-1019504 Carroll BJ (1982) Clinical applications of the dexamethasone supprssion test for endogenous depression. Pharmacopsychiatria 15:19–25
180. 180. BM Kudielka A Buske-Kirschbaum DH Hellhammer C Kirschbaum 2004 HPA axis responses to laboratory psychosocial stress in healthy elderly adults, younger adults, and children: impact of age and gender Psychoneuroendocrinology 29 83 98 14575731 1:CAS:528:DC%2BD3sXot1Gls7w%3D 10.1016/S0306-4530(02)00146-4 Kudielka BM, Buske-Kirschbaum A, Hellhammer DH, Kirschbaum C (2004) HPA axis responses to laboratory psychosocial stress in healthy elderly adults, younger adults, and children: impact of age and gender. Psychoneuroendocrinology 29:83–98
181. 181. JH Meador-Woodruff JF Greden L Grunhaus RF Haskett 1990 Severity of depression and hypothalamic-pituitary-adrenal axis dysregulation: identification of contributing factors Acta Psychiatr Scand 81 364 371 2343764 1:STN:280:DyaK3c3mtFGitQ%3D%3D 10.1111/j.1600-0447.1990.tb05465.x Meador-Woodruff JH, Greden JF, Grunhaus L, Haskett RF (1990) Severity of depression and hypothalamic-pituitary-adrenal axis dysregulation: identification of contributing factors. Acta Psychiatr Scand 81:364–371
182. 182. C Otte M Lenoci T Metzler R Yehuda CR Marmar TC Neylan 2005 Hypothalamic-pituitary-adrenal axis activity and sleep in posttraumatic stress disorder Neuropsychopharmacology 30 1173 1180 15714228 1:CAS:528:DC%2BD2MXltlWmt7s%3D 10.1038/sj.npp.1300676 Otte C, Lenoci M, Metzler T, Yehuda R, Marmar CR, Neylan TC (2005) Hypothalamic-pituitary-adrenal axis activity and sleep in posttraumatic stress disorder. Neuropsychopharmacology 30:1173–1180
183. 183. TE Seeman RJ Robbins 1994 Aging and hypothalamic-pituitary-adrenal response to challenge in humans Endocr Rev 15 233 260 8026389 1:CAS:528:DyaK2cXkt1KqtLY%3D Seeman TE, Robbins RJ (1994) Aging and hypothalamic-pituitary-adrenal response to challenge in humans. Endocr Rev 15:233–260